A risk score model for predicting cardiac rupture after acute myocardial infarction

Yuan Fu, Kui-Bao Li, Xin-Chun Yang

Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

Abstract

Background: Cardiac rupture (CR) is a major lethal complication of acute myocardial infarction (AMI). However, no valid risk score model was found to predict CR after AMI in previous researches. This study aimed to establish a simple model to assess risk of CR after AMI, which could be easily used in a clinical environment.

Methods: This was a retrospective case-control study that included 53 consecutive patients with CR after AMI during a period from January 1, 2010 to December 31, 2017. The controls included 524 patients who were selected randomly from 7932 AMI patients without CR at a 1:10 ratio. Risk factors for CR were identified using univariate analysis and multivariate logistic regression. Risk score model was developed based on multiple regression coefficients. Performance of risk model was evaluated using receiver-operating characteristic (ROC) curves and internal validity was explored using bootstrap analysis.

Results: Among all 7985 AMI patients, 53 (0.67%) had CR (free wall rupture, \( n = 39 \); ventricular septal rupture, \( n = 14 \)). Hospital mortalities were 92.5% and 4.01% in patients with and without CR (\( P < 0.001 \)). Independent variables associated with CR included: older age, female gender, higher heart rate at admission, body mass index (BMI) < 25 kg/m\(^2\), lower left ventricular ejection fraction (LVEF) and no primary percutaneous coronary intervention (pPCI) treatment. In ROC analysis, our CR risk assess model demonstrated a very good discriminate power (area under the curve [AUC] = 0.895, 95% confidence interval: 0.845–0.944, optimism-corrected AUC = 0.821, \( P < 0.001 \)).

Conclusion: This study developed a novel risk score model to help predict CR after AMI, which had high accuracy and was very simple to use.

Keywords: Acute myocardial infarction; Mechanical complications; Cardiac rupture; Risk score model; Primary percutaneous coronary intervention

Introduction

Coronary artery disease (CAD) is a major cause of mortality and morbidity worldwide. Free wall rupture (FWR) is one of the most serious mechanical complications (MCs) of acute myocardial infarction (AMI).\(^{[1,2]}\) The incidence of FWR was 2% to 6.2% in the pre-perfusion era, accounting for up to 30% of mortality after AMI.\(^{[3-5]}\) The incidence of ventricular septal rupture (VSR) after AMI was approximately 1% to 3% before the reperfusion era, with in-hospital mortality rates of about 45% for surgical treatment and 90% for those treated medically.\(^{[6-7]}\) The incidence of MCs after AMI has gone down to less than 1% since the advent of percutaneous coronary intervention (PCI) treatment, but MCs are still associated with extremely poorer outcomes.\(^{[4,6,9]}\) However, no valid risk score model was developed to help to predict cardiac rupture (CR) after AMI in previous researches.

CR was specified as FWR and VSR. The aim of our study was to establish a simple risk score to predict CR after AMI, which can help clinicians in making an early diagnosis and choosing appropriate therapy for better outcomes.

Methods

Ethical approval

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of Beijing Chaoyang Hospital. Since this was a retrospective analysis, informed consent was waived. All data were anonymous and from electronic medical record system.

Patient population and study design

The 53 consecutive patients with CR after AMI referred to Beijing Chaoyang Hospital from January 1, 2010 to...
December 31, 2017 were retrospectively analyzed. The controls were randomly selected from 7932 AMI patients without CR during the same time period at a ratio of 1:10 (n = 524 after excluding six cases with incomplete record). Selection of the cases is shown in Figure 1. Rupture of papillary muscles was not considered for this study.

AMI included ST-segment elevation myocardial infarction (STEMI) and non-STEMI. Diagnostic criteria of STEMI were as follows: (1) typical, prolonged chest pain (>30 min); (2) ST-segment elevation ≥0.2 mV at the J point in two or more contiguous, precordial leads, or ≥0.2 mV in two or more adjacent limb leads on the standard 12-lead electrocardiogram (ECG); and (3) increased serum markers of myocardial damage (≥2-fold increase over the upper normal range required for troponin-I [TnI]). Non-STEMI was defined by ECG ST-segment depression or prominent T-wave inversion and positive biomarkers of necrosis (eg, TNI) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or anginal equivalent).

The diagnosis of FWR was made by echocardiography or in cases with either of sudden cardiogenic shock or low blood pressure associated with large pericardial effusion confirmed by pericardiocentesis. VSR was first suggested by physical examination findings such as cardiac systolic murmur, and it was subsequently confirmed using echocardiography.

**General data collection and anthropometric measurements**

Patient demographics, height, weight, medical and family history, use of medications and smoking status were collected upon patient admission. BMI was calculated as body weight divided by height squared (kg/m²).

The Global Registry of Acute Coronary Events (GRACE) risk score is a validated and established score for risk stratification of patients with ACS, which is calculated from several variables (age, history of heart failure, history of acute myocardial infarction, heart rate and systolic blood pressure at admission, ST-segment depression, serum creatinine at admission, elevated myocardial necrosis markers or enzymes, and lack of percutaneous coronary revascularization during admission). Esti-
mated glomerular filtration rate (eGFR) was calculated according to the Cockcroft-Gault formula.

**Laboratory parameters**

Peripheral blood samples were collected on the first 15 min after admission and analyzed with a Dimension RxL Max™ automated analyzer (Dade Behring Inc., Chicago, Illinois, USA). All biochemical variables were measured using an automatic analyzer (Hitachi 7600, Hitachi Ltd., Tokyo, Japan).

**Statistical analysis**

Normality of variables was tested by Kolmogorov-Smirnov test. Normally-distributed continuous variables are presented as mean±standard deviation (SD), and analyzed using Student’s t-test. Abnormally-distributed data are presented as median (interquartile range), and analyzed using Mann-Whitney U test. Dichotomous variables were analyzed with Pearson Chi-squared test, and expressed as percentages. Risk factors for CR were identified using univariate analysis and multivariate logistic regression. Baseline characteristics associated with CR in univariable analyses with P ≤0.10 were retained for possible inclusion to the final model and entered in a stepwise-backward manner. Risk score model was developed based on multiple regression coefficients. Each coefficient was divided by the smallest coefficient and rounded to the nearest integer. Summation of points assigned for each predictor led to the prediction of CR risk. Discriminatory power was evaluated using the C-index, area under (AUC) the receiver-operating characteristic (ROC) curve with its 95% confidence interval (CI).

A C-index of 0.5 indicates the absence of predictive ability, while a C-index of 1.0 represents perfect discriminatory ability. All these statistical analyses were performed in SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). Internal validity was assessed in 1000 bootstrap samples to estimate the optimism-corrected AUC using the ‘validate’ function from package ‘rms’ in R (R statistical software version 3.4.0). The AUCs were compared using the Z test using MedCalc statistical software version 13.0.2.0 (MedCalc Software, Ostend, Belgium). A P < 0.05 (two-sided) was considered statistically significant.

**Results**

**General characteristics**

Among the 7985 consecutive AMI patients, 53 cases developed CR (0.67%); FWR occurred in 39 patients (0.49%) and VSR in 14 patients (0.18%). The average observational period from AMI onset to HR was 3.1 days (FWR=2.7 days, VSR=3.6 days). The 19 patients (48.7%) developed with FWR and six patients (42.9%) developed with VSR within 24 h after symptoms onset; five
| Variables                      | FWR patients (n=39) | VSR patients (n=14) | Total (n=53) | Non-CR patients (n=524) | Statistical values | P   |
|-------------------------------|---------------------|---------------------|--------------|-------------------------|--------------------|-----|
| Age (years)                   | 75.6±5.6            | 74.4±4.1            | 75.3±5.2     | 66.2±9.8                | 7.48               | <0.001 |
| Female                        | 23 (59)             | 7 (50)              | 30 (56.6)    | 142 (27.1)              | 12.99              | <0.001 |
| HT                            | 26 (66.7)           | 9 (64.3)            | 35 (66)      | 372 (71)                | 0.41               | 0.527 |
| DM                            | 8 (20.5)            | 4 (28.6)            | 12 (22.6)    | 126 (24)                | 0.74               | 0.323 |
| CHF                           | 1 (2.6)             | 0                   | 1 (1.9)      | 16 (3.1)                | 0.03               | 0.955 |
| History of stroke or TIA      | 9 (23.1)            | 1 (7.1)             | 10 (18.9)    | 95 (18.1)               | 0.11               | 0.773 |
| History of MI                 | 2 (5.1)             | 2 (14.3)            | 4 (7.5)      | 32 (9.9)                | 0.25               | 0.617 |
| History of CAD                | 6 (15.4)            | 2 (14.3)            | 8 (15.1)     | 100 (19.1)              | 0.36               | 0.547 |
| History of PCI                | 3 (7.7)             | 1 (7.1)             | 4 (7.5)      | 74 (14.1)               | 1.89               | 0.183 |
| History of CAGB               | 0                   | 0                   | 0            | 10 (1.9)                | 0.76               | 0.300 |
| History of AF                 | 4 (10.3)            | 2 (14.3)            | 6 (11.3)     | 26 (5.0)                | 2.07               | 0.15  |
| Current smoker                | 20 (51.3)           | 6 (42.9)            | 26 (49.1)    | 314 (59.9)              | 1.69               | 0.194 |
| BMI (kg/m²)                   | 24.0±3.3            | 23.6±3.5            | 24.0±3.4     | 25.4±3.4                | -2.56              | 0.111 |
| Symptom onset time (h)        | 24.0 (8.0, 72.0)    | 84.0 (10.0, 174.0)  | 24.0 (8.5, 72.0) | 12.0 (6.0, 48.0) | 4.82 | 0.012 |
| STEMI                         | 32 (82.1)           | 10 (71.4)           | 42 (79.2)    | 346 (66.0)              | 2.93               | 0.087 |
| Heart rate (beats/min)        | 94.68±17.81         | 101.21±20.96        | 99.11±19.73  | 76.52±14.1              | 4.12               | <0.001 |
| SBP (mmHg)                    | 124.74±26.45        | 110.64±22.44        | 121.02±26.01 | 128.33±22.1             | -1.74              | 0.069 |
| Killip class                  | I                   | 8 (20.5)            | 1 (7.1)      | 9 (17)                  | 22.62              | <0.001 |
|                              | II                  | 20 (51.3)           | 9 (64.3)     | 29 (54.7)               | 6.14               | 0.013 |
|                              | III                 | 5 (12.8)            | 2 (14.3)     | 7 (13.2)                | 3.23               | 0.037 |
|                              | IV                  | 6 (15.4)            | 2 (14.3)     | 8 (15.1)                | 3.90               | 0.015 |
| Location of MI               | Anterior            | 21 (53.8)           | 7 (50.0)     | 28 (52.8)               | 0.06               | 0.814 |
|                              | Inferior            | 24 (61.5)           | 6 (42.9)     | 30 (56.7)               | 0.97               | 0.237 |
|                              | Posterior           | 7 (17.9)            | 4 (28.6)     | 11 (20.8)               | 0.23               | 0.636 |
|                              | Lateral             | 14 (35.9)           | 4 (28.6)     | 18 (34.0)               | 0.17               | 0.685 |
|                              | Multiple            | 25 (64.1)           | 8 (57.1)     | 33 (62.3)               | 1.01               | 0.234 |
| β-RB within 24 h             | 13 (33.3)           | 7 (50.0)            | 20 (37.7)    | 262 (50.0)              | 2.62               | 0.147 |
| ACE/ARB within 24 h          | 2 (5.1)             | 0                   | 2 (3.8)      | 79 (15.1)               | 4.42               | 0.036 |
| ESR (mm/h)                   | 21.0 (9.0, 30.0)    | 24.0 (19.8, 37.3)   | 23.0 (11.5, 31.0) | 9 (4.0, 19.0) | 10.52 | <0.001 |
| NT-proBNP (pg/mL)            | 2540.0 (12320.0, 4777.0) | 5563.0 (24988.0, 9977.8) | 3321.0 (13820.0, 58185.0) | 1812.5 (6820.0, 26310.0) | 19.05 | <0.001 |
| WBC (×10³/L)                 | 12.13±4.9           | 11.79±4.41          | 12.04±4.74   | 8.78±2.73               | 4.62               | <0.001 |
| RBC (×10¹²/L)                | 4.04±0.53           | 3.87±0.63           | 4.00±0.36    | 4.30±0.73               | -2.45              | 0.009 |
| Hb (g/L)                     | 123.97±16.52        | 119.86±18.45        | 122.9±16.97  | 131.53±20.1             | -2.67              | 0.006 |
| D-dimer (mg/L FEU)           | 1.37±1.27           | 2.02±1.74           | 1.54±1.42    | 0.85±3.48               | 1.38               | 0.086 |
| CK-MB (ng/mL)                | 57.90 (10.80, 156.30) | 34.40 (5.43, 152.15) | 47.70 (7.55, 148.90) | 17.25 (3.93, 76.43) | 5.71 | 0.017 |
| CTnI (ng/mL)                 | 32.53 (6.76, 57.80) | 7.42 (5.48, 25.09)  | 20.36 (6.05, 42.13) | 7.82 (1.69, 35.17) | 6.41 | 0.011 |
| LDL (mmol/L)                 | 2.47±0.97           | 2.76±0.79           | 2.54±0.93    | 2.55±0.84               | -0.02              | 0.983 |
Table 1

| CR patients | Non-CR patients |
|-------------|----------------|
| Total CR patients | Non-CR patients |
| n | Statistical values |
| Variables | Total CR patients (n = 524) | VSR patients (n = 53) | Non-CR patients (n = 50) |
| SCR (μmol/L) | 101.42 ± 51.79 | 120.86 ± 44.31 | 106.56 ± 50.26 |
| eGFR (ml min⁻¹ 1.73 m⁻²) | 79.16 ± 30.48 | 84.91 ± 28.16 | 77.30 ± 28.46 |
| BUN (mg/dL) | 33.83 ± 9.58 | 48.30 ± 14.10 | 42.14 ± 10.75 |
| LVEF (%) | 58.55 ± 5.73 | 66.77 ± 5.83 | 68.04 ± 5.92 |
| Mortality | 11.78 (3.14) | 19.33 (6.67) | 21.40 (6.40) |

Data are shown as mean ± standard deviation (SD).

**Table 1 (continued)**

| Variables | FWR patients (n = 39) | VSR patients (n = 14) |
|-----------|-----------------------|----------------------|
| SCR (μmol/L) | 101.42 ± 51.79 | 120.86 ± 44.31 |
| eGFR (ml min⁻¹ 1.73 m⁻²) | 79.16 ± 30.48 | 84.91 ± 28.16 |
| BUN (mg/dL) | 33.83 ± 9.58 | 48.30 ± 14.10 |
| LVEF (%) | 58.55 ± 5.73 | 66.77 ± 5.83 |
| Mortality | 11.78 (3.14) | 19.33 (6.67) |

**GrACE risk score and ROC curve analysis**

The GrACE risk score of FWR and VSR patients was 195.15 ± 38.77 and 209.86 ± 46.56, respectively. CR patients had a significantly higher GrACE risk score than patients without CR (198.04 ± 41.03 vs. 165.32 ± 37.54, P < 0.001). A receiver operating characteristic (ROC) curve analysis was performed and area under the ROC curve (AUC) of the GrACE risk score model to predict CR after AMI was 0.716 (95% CI: 0.634–0.798, P < 0.001) [Figure 2].

**Multivariable analysis and ROC curve analysis**

We used the stepwise backward method to fit the multivariate logistic regression model. The inclusion criteria was P ≤ 0.10, and the exclusion criteria was P ≥ 0.05. In multivariate logistic regression, six factors were associated with CR independently: older age, female, higher heart rate at admission, no pPCI treatment, lower LVEF, and lower BMI [Table 3].

A ROC analysis serves to determine the optimal cut-off point of age, heart rate at admission and LVEF for identifying patients with CR. The criterion for optimal cut-off point selection is the maximum of the Youden index.[21] Age of 68 years, heart rate of 94 beats/min and LVEF of 40% were the optimal cut-off points, respectively. The effect of BMI was assessed as a continuous variable and according to two categories using the cut-off of 25.0 kg/m², attending to what is considered overweight and obesity.[22,23]

Another multivariable analysis was performed and according to multivariate regression coefficients, different weighted scores were assigned to each risk factor [Table 4]. A risk score model (0–12) was established. The mean score of all participants was 5.59 ± 3.27. CR patients had a significantly higher score than non-CR patients (8.57 ± 1.83 vs. 4.02 ± 2.73, P < 0.001). The mean score of FWR and VSR patients was 8.28 ± 1.9 and 9.35 ± 1.39. The incidence of CR altered from scores and was increased along with the risk score in a nearly linear manner: score 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 in order. The cut-off point of 7 significantly increases the probability of CR [Table 4].
We categorized patients into three groups: low risk (score ≤ 3), moderate risk (4–7) and high risk (≥ 8) groups. We found that the risk of CR in these three groups were 0%, 23.3% and 81.3%, respectively. This CR risk score model demonstrated a very good discriminate power in ROC curve analysis (AUC = 0.843, 95% CI: 0.781–0.905, optimism-corrected AUC = 0.821, P < 0.001) [Figure 3]. The 48 in-hospital CR events could be predicted using our risk score model and the P value of Hosmer-Lemeshow goodness-of-fit was 0.67.

**Discussion**

In the present study, we found several risk factors associated with CR and established a risk score model to predict CR after AMI. To the best of our knowledge, this study early reported such a simple model with very high discriminate power in predicting CR after AMI.

CR was one of the most serious complications after AMI, though its incidence decreased dramatically with the widespread use of thrombolytics, PCI and modern therapies.\[4,8,9\] In some reports during the pre-reperfusion era, CR occurred in as many as 6% of all cases admitted for AMI.\[8\] Most of the contemporary studies, including large registries and clinical trials like the GRACE registry, report an incidence of CR after AMI around 1%, similar to the present study (0.67%).\[10,24,25\] CR, in particular FWR, is considered to be a hopeless complication after AMI. Despite advances in diagnostic procedures and surgical techniques, hospital mortality remains high in patients with CR. The hospital mortality of CR patients was 92.5% in the present study, with 97.4% in FWR and 78.6% in VSR patients, respectively. Similar or a little lower mortality rates have been observed in other modern studies.\[1,5,26\] CR occurred more frequently in women and older patients. Longer symptom onset time, higher heart rate at admission, KILLIP class, ESR, Nt-proBNP, WBC, CKMB, CTNI, GRACE risk score, in hospital infection, hemorrhage and mortality was also seen in CR patients. Moreover, CR group had significantly lower BMI, ACEI/ARB use in 24 h after admission, Rbc, eGFR, and pPCI treatment. Most of these CR related factors have also been reported previously.\[27-30\] In the multivariable analysis, older age, female gender, higher heart rate at admission, lower LVEF, lower BMI and no pPCI treatment related independently to CR.

Of all factors related to CR, age is probably the most relevant. Older age was invariably reported in many previous studies as the leading risk factor for CR.\[29,31,32\] Same results were shown in our study as well. Many studies have reported the association between BMI and outcomes of patients with acute coronary syndromes (ACS). For example, in a retrospective study of 413,673 patients with AMI, higher BMI patients had the lowest odds of in-hospital mortality.\[33\] Later, several studies also concluded that in patients with AMI, short-term, medium-term, and long-term mortality rates were all lower in the overweight, obese and morbidly obese groups compared with the normal weight group.\[34,35\] In the present study, we found BMI level was significantly lower in CR group and BMI < 25 kg/m² was an independent risk factor for CR in AMI patients.

The frequency of CR has two peaks: an early peak within 24 h and a late one from 4 to 6 days.\[36-38\] Similar results also found in our study. Early rupture (within 24 h) is related to the initial evolution of infarction before significant collagen deposition, and late rupture (≥ 24 h) is related to expansion of the infarct-related ventricular wall.\[37\] Primary PCI treatment seems to provide protection against CR, independent of other factors.\[7,8\] There
are two main factors to explain why CR occurs less frequently with PCI treatment than with traditional thrombolysis therapy: first, PCI treatment achieves the restoration of coronary patency more frequently and second, the risk of bleeding is much lower. Previous studies have reported coronary single-vessel disease as an independent risk factor for CR, consistent with previous research conclusions. Previous studies have reported coronary single-vessel disease as a predictor of adverse outcomes in ACS patients and current guidelines recommend using the GRACE risk score for risk stratification in ACS patients. However, the value of the GRACE risk score in predicting CR after AMI was rarely reported, and should probably not be used to predict CR. Similar results were presented in our study: although CR patients had a significantly higher GRACE risk score than non-CR patients (198.04±165.32 vs. 165.32±37.54, P<0.001), the discriminate power of the GRACE risk score than non-CR patients (198.04±165.32 vs. 165.32±37.54, P<0.001), the discriminate power of the GRACE risk score in predicting CR seemed unsatisfactory after ROC curve analysis (AUC=0.716, 95%CI 0.634–0.798, P<0.001).

Risk stratification is essential for the comprehensive management of patients with ACS. Prompt diagnosis with appropriate medical therapy and timely surgical intervention are necessary for favorable outcomes of CR patients. To the best of our knowledge, there was no valid risk model to predict CR after AMI reported before. The GRACE risk score in predicting CR after AMI was rarely reported, and should probably not be used to predict CR. Similar results were presented in our study: although CR patients had a significantly higher GRACE risk score than non-CR patients (198.04±165.32 vs. 165.32±37.54, P<0.001), the discriminate power of the GRACE risk score in predicting CR seemed unsatisfactory after ROC curve analysis (AUC=0.716, 95%CI 0.634–0.798, P<0.001).

Table 3: Univariable analysis of factors associated with CR in patients with AMI.

| Variables                          | β      | OR     | 95% CI       | P    |
|-----------------------------------|--------|--------|--------------|------|
| Age (years)                       | 5.196  | 7.217  | 2.131–15.125 | <0.001|
| Female                            | 1.411  | 2.709  | 1.319–7.01   | <0.001|
| BMI (kg/m²)                       | -0.591 | 1.743  | 0.771–3.941  | 0.011 |
| Symptom onset time (h)            | 0.047  | 1.207  | 0.996–1.891  | 0.012 |
| STEMI                             | 0.876  | 1.967  | 0.9–4.301    | 0.087 |
| Heart rate (beats/min)            | 0.934  | 2.635  | 1.326–5.437  | <0.001|
| SBP (mmHg)                        | -0.13  | 0.987  | 0.972–1.011  | 0.069 |
| KILLIP class                      | -0.272 | 0.993  | 0.44–2.24    | <0.001|
| ACEI/ARB within 24 h              | -1.504 | 0.222  | 0.149–1.012  | 0.036 |
| ESR (mm/h)                        | 0.45   | 1.046  | 1.02–1.074   | 0.012 |
| NT-proBNP (pg/mL)                 | 0.709  | 1.312  | 0.99–1.817   | 0.331 |
| WBC (×10^9/L)                     | 0.264  | 1.303  | 1.156–1.467  | <0.001|
| RBC (×10^12/L)                    | -0.761 | 0.467  | 0.252–0.866  | 0.009 |
| Hb (g/L)                          | -0.025 | 0.785  | 0.857–0.995  | 0.006 |
| D-dimer (mg/L FEU)                | 0.098  | 1.103  | 0.914–1.330  | 0.086 |
| CK-MB (ng/mL)                     | 0.035  | 1.005  | 0.998–1.015  | 0.017 |
| CTnI (ng/mL)                      | 0.003  | 0.997  | 0.888–1.012  | 0.011 |
| eGFR (mL/min·1.73 m^2)            | -0.16  | 0.981  | 0.969–1.048  | 0.001 |
| LVEF (%)                          | -0.475 | 1.298  | 0.324–5.567  | <0.001|
| No pPCI treatment                 | 1.065  | 2.902  | 1.254–6.204  | <0.001|
| Infection                         | 1.691  | 2.577  | 1.140–5.523  | <0.001|
| Hemorrhage                        | 0.621  | 1.844  | 0.256–13.299 | 0.001 |

ACEI: Angiotensin-converting enzyme inhibitor; AMI: Acute myocardial infarction; ARB: Angiotensin receptor blocker; BMI: Body mass Index; CI: Confidence interval; CK-MB: Creatine kinase MB; CR: Cardiac rupture; CTnI: Cardiac troponin I; eGFR: Estimated glomerular filtration rate; ESR: Erythrocyte sedimentation rate; Hb: Hemoglobin; LVEF: Left ventricular ejection fraction; NT-proBNP: N-terminal B-type natriuretic peptide; OR: Odds ratio; pPCI: Primary percutaneous coronary intervention; RBC: Red blood cell; STEMI: ST-segment elevation myocardial infarction; SBP: Systolic blood pressure; SUA: Serum uric acid; WBC: White blood cell.

Table 4: Multiple analyses of factors associated with CR in AMI patients and predicting risk score model.

| Variables                          | β      | OR     | 95% CI       | P    | Weighted score |
|-----------------------------------|--------|--------|--------------|------|----------------|
| Female                            | 1.068  | 2.909  | 1.219–6.94   | 0.002| 2              |
| No pPCI treatment                 | 1.064  | 2.897  | 1.245–6.742  | 0.017| 2              |
| LVEF < 40%                        | 0.464  | 1.591  | 0.444–5.695  | 0.010| 1              |
| Heart rate ≥ 94 beats/min         | 1.1    | 3.003  | 1.279–7.049  | 0.001| 2              |
| BMI < 25 kg/m²                    | 0.453  | 1.573  | 0.667–3.708  | 0.029| 1              |
| Age ≥ 68 years                    | 1.996  | 7.358  | 2.311–16.425 | 0.004| 4              |

AMI: Acute myocardial infarction; BMI: Body mass Index; CI: Confidence interval; CR: Cardiac rupture; LVEF: Left ventricular ejection fraction; OR: Odds ratio; pPCI: Primary percutaneous coronary intervention.
Six factors: female, no pPCI treatment, LVEF < 40%, heart rate ≥ 94 beats/min, BMI < 25 kg/m² and age ≥ 68 years were found to be associated with CR independently in the present study. After assigned to different weighted scores according to regression coefficients, a simple risk score system ranged from 0 to 12 was established to predict CR after AMI. After ROC curve analysis, this new risk score demonstrated a very good discriminate power (AUC = 0.843, 95% CI: 0.781–0.905, optimism-corrected AUC = 0.821, P < 0.001). Using our risk score model, 48 in-hospital CR events can be predicted (very close to the actual 53 CR events) and the value of Hosmer-Lemeshow goodness-of-fit was 0.67. The AUC for our risk score model was statistically higher than the AUC for the GRACE risk score (0.843 vs. 0.716, P < 0.001), which demonstrated that the predictive value of our risk model was significantly better than the GRACE risk score.

There were several limitations to the current study. First, as a retrospectively case-control study with relatively small sample size, the potential cause-effect relationship could not be determined. Second, no validation cohort was set up to verify the predictive value of our risk score. Third, we did not obtain all patients’ information about collateral vessels formation.

In conclusion, the risk score model this study established was simple to use, and with high predictive accuracy in predicting CR after AMI.

Conflicts of interest
None.

References
1. Pohjola-Sintonen S, Muller JE, Stone PH, Willich SN, Antman EM, Davis VG, et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the multicenter investigation of limitation of infarct size. Am Heart J 1989;117:809–818. doi: 10.1016/0002-8703(89)90617-0.
2. Opaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiological features to the role of invasive and noninvasive diagnostic modalities in current management. Am J Med 1992;93:683–688. doi: 10.1016/0002-9343(92)90203-N.
3. López-Sendón J, González A, de Sá EL, Coma-Canela I, Roldán I, Dominguez F, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: Sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. JACC 1992;19:1145–1153. doi: 10.1016/0735-1077(92)90315-e.
4. Becker RC, Gore JM, Lamber C, Douglas Weaver W, Michael Rubison R, French WJ, et al. A composite view of cardiac rupture in the United States national registry of myocardial infarction. JACC 1996;27:1321–1326. doi: 10.1016/0735-1077(96)00008-3.
5. Slater J, Brown RJ, Antonelli TA, Menon V, Boland J, Col J, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. JACC 2000;36:1117–1122. doi: 10.1016/S0735-1077(00)00845-7.
6. Başaj A, Sethi A, Rathor P, Suppougu N, Sethi A. Acute complications of myocardial infarction in the current era: diagnosis and management. J Investig Med 2015;63:844–855. doi: 10.1077/jim.00000000000232.
7. Moreno R, López-Sendón J, García E, de Isla LP, de Sá EL, Ortega A, et al. Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. JACC 2002;39:598–603. doi: 10.1016/S0735-1077(01)01794-x.
8. Figueras J, Alcalde O, Barrabes JA, Serra V, Alguersuari J, Cortadellas J, et al. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation 2008;118:2783–2789. doi: 10.1161/CIRCULATIONAHA.108.776690.
9. Becker RC, Charlesworth A, Wilcox RG, Hampton J, Skene A, Gore JM, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study. JACC 1995;25:1063–1068. doi: 10.1016/S0735-1077(94)00324-4.
10. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. JACC 2004;44:671–719. doi: 10.1016/j.jacc.2004.07.002.
11. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. ACC/AHA guidelines for the management of patients with non-st-elevation acute coronary syndromes: executive summary. JACC 2014;64:2645–2687. doi: 10.1016/j.jacc.2014.09.016.
12. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091. doi: 10.1136/bmj.3895.64681.55.
13. Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, Lopez-Sendon J, Van de Werf F, et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 2007;93:177–182. doi: 10.1136/hrt.2005.084830.
14. Tang EW, Wong C-K, Heribson P, Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007;153:29–35. doi: 10.1016/j.ahj.2006.10.004.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. doi: 10.1159/000180580.
16. Scrutton D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, et al. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/Nt-proBNP risk score. Int J Cardiol 2013;168:2120–2126. doi: 10.1016/j.ijcard.2013.01.005.
